Cristina Banfi, Maura Brioschi, Minna K. Karjalainen, Johanna M. Huusko, Erica Gianazza, Piergiuseppe Agostoni, Immature surfactant protein-B impairs the antioxidant capacity of HDL, International Journal of Cardiology, Volume 285, 2019, Pages 53-58, ISSN 0167-5273, https://doi.org/10.1016/j.ijcard.2019.02.057
Immature surfactant protein-B impairs the antioxidant capacity of HDL
|Author:||Banfi, Cristina1; Brioschi, Maura1; Karjalainen, Minna K.2,3;|
1Centro Cardiologico Monzino, IRCCS, Milano, Italy
2PEDEGO Research Unit, Medical Research Center Oulu, University of Oulu, Oulu, Finland
3Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland
4Dipartimento di Scienze Cliniche e di Comunità, Sezione Cardiovascolare, Università di Milano, Italy
|Online Access:||PDF Full Text (PDF, 2.5 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2019070322659
|Publish Date:|| 2020-06-15
Circulating immature surfactant protein B (proSP-B) forms emerged as the most reliable lung-specific circulating marker for alveolar-capillary membrane (ACM) dysfunction and for the overall clinical status of heart failure (HF). Notably, in terms of HF hospitalization, immature SP-B overwhelms the prognostic role of other most frequently used clinical parameters such as those related to lung dysfunction. The strong prognostic value of circulating proSP-B in HF suggests more widespread and possible systemic effects. Thus, we assessed the plasma distribution of proSP-B evaluating whether it exists in a lipoprotein-bound form and its impact on lipoprotein structure and function. ProSP-B forms were detectable in high-density lipoprotein (HDL) only. To assess the impact of proSP-B on HDL, HDL from healthy subjects were enriched with proSP-B produced by a stably transfected CHO cell line that specifically expresses and releases the human proSP-B. After enrichment, HDL size and lipoprotein electrophoretic mobility, and protein composition did not show apparent differences. HDL antioxidant capacity (HOI), assessed as their ability to inhibit air-induced LDL oxidation, was impaired after proSP-B enrichment. HOI was also higher in HF patients with respect to age-matched control healthy subjects (p = 0.013). Circulating proSP-B, besides its potential role as a specific marker for ACM dysfunction in HF patients with diagnostic and prognostic value, binds to human HDL impairing their antioxidant capacity. These findings shed light on proSP-B as a molecule that contributes to the reduction of the defense against oxidative stress, a key mediator in the pathogenesis of HF.
International journal of cardiology
|Pages:||53 - 58|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
1182 Biochemistry, cell and molecular biology
3121 General medicine, internal medicine and other clinical medicine
This work was supported by the Italian Ministry of Health, Italy (Ricerca Corrente 2014 BIO15 ID 2607391).
© 2019 Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.